Seattle Genetics' Padcev Exceeds Expectations Despite Pandemic

Strategic Insights -

Seattle Genetics' Padcev, a new bladder cancer treatment, exceeded sales estimates by four- to fivefold in its first quarter on the market, generating $34.5 million in sales. The drug's impressive performance has led analysts to revise their sales estimates, with some projecting peak sales of $2 billion in relapsed or refractory bladder cancer and $5.8 billion in previously untreated patients. Even though other drugmakers have seen Q1 sales boosted by stockpiling, Padcev's "just in time" delivery model and continued adoption by patients indicate that its success is not a one-time fluke.

Key Takeaways:

  • Padcev exceeded sales estimates by four- to fivefold, generating $34.5 million in sales in its first quarter on the market.
  • Analysts are revising their sales estimates for Padcev, with some projecting peak sales of $2 billion in relapsed or refractory bladder cancer.
  • SVB Leerink's Andrew Berens estimates peak sales in relapsed or refractory bladder cancer to be $2 billion and previously untreated patients to be $5.8 billion.
  • Padcev's "just in time" delivery model contributed to its success, as it is less likely to be driven by stockpiling.
  • The continued adoption of Padcev by patients, even in the midst of the pandemic, suggests that the drug's performance was not a one-time fluke.
  • Seattle Genetics is pursuing a phase 3 trial for Padcev in previously untreated patients, who make up a "sizable" market.

Statistics:

  • $34.5 million: Padcev's sales in its first quarter on the market.
  • 4.5 months: The expected duration of treatment for Padcev in relapsed or refractory bladder cancer.
  • 10,000: The estimated number of MIBC patients in the U.S. who could benefit from Padcev.
  • $2 billion: SVB Leerink's peak sales projection for Padcev in relapsed or refractory bladder cancer.
  • $5.8 billion: SVB Leerink's peak sales projection for Padcev in previously untreated patients.

Sources:

  • J.P. Morgan analyst Cory Kasimov
  • SVB Leerink analyst Andrew Berens
  • Seattle Genetics' management, who cited assurances that many patients who received Padcev in Q1 are still alive and receiving therapy.